

down on Plaintiffs” who had repeatedly answered they would not dispense methotrexate “because doing so would ‘knowingly’ be providing a means to end human life.” *Texas v. United States Dep’t of Health & Hum. Servs.*, No. 23–CV–00022–DC, 2024 WL 1493809, at *6 (W.D. Tex. Apr. 5, 2024). The court summarized the ensuing colloquy:

Much to the Court’s surprise, Defendants’ answer at the summary judgment hearing was a resounding no. In fact, the Defendants stated that even “if OCR received a complaint, OCR would determine on the basis of the complaint that it is invalid.” And when the Court pressed the hypothetical again, Defendants affirmed once more “if HHS received a complaint based on that, HHS would quickly reject that complaint because in HHS’s view, that is not a violation of law. And that’s certainly not something that HHS would go out of its way to investigate.”

The Court then changed the question slightly, asking Defendants if OCR would investigate if the pharmacy’s reason for not dispensing the drugs was *because* the woman was pregnant—which seemingly would violate Title IX’s prohibition on pregnancy discrimination. Defendants responded with the same answer: “if that complaint came before HHS, HHS would quickly reject it because its position is that that’s not a violation of the law.”

Id. at *6.⁷ Thus, considering that these verbal concessions (a literal “surprise” to the presiding judge based upon a plain reading of the 2023 Guidance) were needed to convince a federal judge that it was legally defensible, OCR finds it is difficult to maintain that the 2023 Guidance advances the best reading of the civil rights statutes enforced by OCR. The language of the 2023 Guidance requires pharmacies to stock and fill prescriptions for drugs such as methotrexate and misoprostol, even if the pharmacist objects due to their potential abortion-related uses. When the 2023 Guidance is considered in light of HHS’s assurances to the court that it would not pursue investigations of such actions the 2023 Guidance purports to prohibit, it is confusing (and potentially misleading) to the public and regulated entities.

In furtherance of the requirements in sections 2(a)(iii) and 3 of E.O. 14219 to identify, deprioritize, and rescind guidance documents that “are based on anything other than the best reading of

⁷Based on this discussion, the court concluded that “OCR’s enforcement hammer” would not “come crashing down on Plaintiffs” for not dispensing methotrexate. *Id.* at *1, *6–*8. The court concluded that the revised guidance, with HHS’s assurances, did not require the plaintiffs to dispense drugs for abortion purposes, or for non-abortion purposes if it would violate Texas law or plaintiffs’ sincerely held religious beliefs. *Id.* at *8.

the underlying statutory authority or prohibition,”⁸ OCR is rescinding this guidance.

Finally, the 2023 Guidance uses the phrase “pregnant person.” This term is inconsistent with E.O. 14148 “Initial Rescissions Of Harmful Executive Orders And Actions,” which repealed E.O. 13988 on “Preventing and Combating Discrimination on the Basis of Gender Identity or Sexual Orientation,” and with E.O. 14168 “Defending Women From Gender Ideology Extremism And Restoring Biological Truth To The Federal Government.” E.O. 14168 defines a “woman” or a “girl” as “female” based on biological facts and rejects efforts to “invalidate” the biological category of “woman.” Accordingly, the term “pregnant person” is unnecessarily broad since only women and girls can be pregnant.

The 2023 Guidance is rescinded.

III. Collection of Information Requirements

This Notice creates no legal obligations and no legal rights. Because this Notice imposes no information collection requirements, it need not be reviewed by the Office of Management and Budget under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 *et seq.*).

Dated: January 21, 2026.

Paula M. Stannard

Director, Office for Civil Rights, Department of Health and Human Services.

[FR Doc. 2026–01550 Filed 1–23–26; 11:15 am]

BILLING CODE 4153–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Complementary & Integrative Health; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Advisory Council for Complementary and Integrative Health, April 17, 2026, 10:00 a.m. to April 17, 2026, 05:00 p.m., National Institutes of Health, DEM 2, 6707 Democracy Boulevard, Bethesda, MD 20892 which was published in the **Federal Register** on December 16, 2025, 90 FR 58257.

This amendment reflects the new end time for the NACCIH Advisory Council Meeting, with the Closed Session

⁸E.O. 14219, *Ensuring Lawful Governance and Implementing the President’s ‘Department Of Government Efficiency’ Deregulatory Initiative*, 90 FR 10583 at 2(a)(iii) (Feb. 19, 2025).

ending at 11:30 a.m. and the Open Session starting at 12:00 p.m. The Open Session will be broadcast to the public. The meeting is partially Closed to the public.

Dated: January 22, 2026.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–01561 Filed 1–26–26; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–7106–N–11]

Privacy Act of 1974; System of Records

AGENCY: Office of Administration HUD.
ACTION: Notice of a modified system of records.

SUMMARY: Under the Privacy Act of 1974, as amended, the Department of Housing and Urban Development (HUD), Office of Administration, Office of the Executive Secretariat (Exec Sec) is issuing a public notice of its intent to modify the Privacy Act system of records titled “Correspondence Tracking System (CTS)”. This system of records is being revised to make clarifying changes within: System Location, System Manager(s), Categories of Records in the System, and Policies and Practices for Retrieval of Records.

DATES: *Comments will be accepted on or before* February 26, 2026: This SORN becomes effective immediately.

ADDRESSES: You may submit comments, identified by docket number or by one of the following methods:

Federal e-Rulemaking Portal: <http://www.regulations.gov>. Follow the instructions provided on that site to submit comments electronically.

Fax: 202–619–8365.

Email: privacy@hud.gov.

Mail: Attention: Privacy Office; Shalanda Capehart, Acting Chief Privacy Officer; The Executive Secretariat; 451 Seventh Street SW, Room 10139; Washington, DC 20410–0001.

Instructions: All submissions received must include the agency name and docket number for this rulemaking. All comments received will be posted without change to <http://www.regulations.gov> including any personal information provided.

Docket: For access to the docket to read background documents or comments received go to <http://www.regulations.gov>.